Cargando…
High EGFR and low p-Akt expression is associated with better outcome after nimotuzumab-containing treatment in esophageal cancer patients: preliminary clinical result and testable hypothesis
The epidermal growth factor receptor (EGFR) is widely overexpressed in esophageal squamous cell carcinoma (ESCC) and it results is associated with a poor prognosis. Identifying the subgroup of ESCC patients who are sensitive to EGFR-targeted therapy is a key point to facilitate its medical use. We r...
Autores principales: | Wang, Chun-yu, Deng, Jia-ying, Cai, Xu-wei, Fu, Xiao-long, Li, Yuan, Zhou, Xiao-yan, Wu, Xiang-hua, Hu, Xi-chun, Fan, Min, Xiang, Jia-qing, Zhang, Ya-wei, Chen, Hai-quan, Perez, Rolando, Jiang, Guo-liang, Zhao, Kuai-le |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4621919/ https://www.ncbi.nlm.nih.gov/pubmed/26124180 |
Ejemplares similares
-
EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab's Clinical Effects
por: Perez, Rolando, et al.
Publicado: (2011) -
Nimotuzumab combined with radiotherapy for esophageal cancer: preliminary study of a Phase II clinical trial
por: Liang, Jun, et al.
Publicado: (2013) -
Akt and mTORC1 signaling as predictive biomarkers for the EGFR antibody nimotuzumab in glioblastoma
por: Ronellenfitsch, Michael W., et al.
Publicado: (2018) -
The Neural Basis of Testable and Non-Testable Beliefs
por: Howlett, Jonathon R., et al.
Publicado: (2015) -
Perturbation of Thymocyte Development Underlies the PRRS Pandemic: A Testable Hypothesis
por: Butler, John E., et al.
Publicado: (2019)